Anthos Therapeutics' abelacimab shows lower bleeding risk vs Xarelto in atrial fibrillation trial, with 62% reduction in ...

FDA adds boxed warning to Teva's Copaxone and generic versions after serious allergic reactions, including anaphylaxis that ...

A little-known Chinese biotech startup has zipped ahead of US companies in one of the gene editing field’s most competitive ...

The FDA dodged claims from Vanda Pharmaceuticals that it allegedly violated the US Constitution by recommending the same drug ...

On the J&J's fourth-quarter earnings call, executives stood by Intra-Cellular’s projection that Caplyta could eclipse $5 ...

Samsung Biologics closed 2024 on several high notes, reaching its highest annual revenue to date — and just a week ago, ...

HHS Secretary nominee Robert F. Kennedy Jr. will divest his interests in several biopharma companies, including CRISPR ...

Quantum Health laid off 4% of workforce shortly after naming Dayne Williams as CEO. The company serves 3M+ members for ...

Xilio's vilastobart plus Roche's Tecentriq shows partial responses in colorectal cancer trial, but company faces cash ...

AstraZeneca says it plans to participate in the next round of Medicare negotiations under the Inflation Reduction Act. But this time around, the company says it’s dealing with a whole different set of ...

Stanford University professor Irv Weissman and a colleague published a paper that represented a new way to target some ...

J&J's depression drug Spravato hits $1B in 2024 sales, up 56% from 2023, with expanded label approval and 140,000+ patients ...